Search Results

Neurocentria Inc., a privately held late-stage biotechnology company developing novel therapies for Alzheimer’s disease, Attention Deficit Hyperactivity Disorder, Major Depressive Disorder and other neurodegenerative and neuropsychiatric disorders, has published a novel research paper identifying magnesium’s key role in synaptic and cognition regulation.

Neurocentria, Inc. has today announced that Dr. Thomas Südhof, Avram Goldstein Professor in Stanford University School of Medicine and an investigator of the Howard Hughes Medical Institute, has joined the company’s Scientific Advisory Board (SAB).

Neurocentria Inc., has received FDA approval to conduct a pivotal phase IIb/III human clinical trial to test the efficacy and safety of its leading drug candidate NRCT-101SR compared to inactive placebo in adults with ADHD.

◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.